# Dual HER2 blockade

Source: https://onco.cc/terms/dual-her2-blockade/  
OnCo record `dual-her2-blockade` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Using two HER2 antibodies (trastuzumab and pertuzumab) at once, which works better than one.

## Summary

Trastuzumab (domain IV) plus pertuzumab (domain II) block ligand-independent and ligand-dependent signalling and enhance ADCC. CLEOPATRA (OS +16 months), NeoSphere (pCR), and APHINITY (node-positive iDFS) established it; Phesgo delivers both subcutaneously. Now being paired with T-DXd (DESTINY-Breast09) and tucatinib (HER2CLIMB-05).

## Fields

- Kind: Term
- Last checked: 2026-09-07

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Pertuzumab
- ClinicalTrials.gov NCT00567190: CLEOPATRA: https://clinicaltrials.gov/study/NCT00567190
- ClinicalTrials.gov NCT01358877: APHINITY: https://clinicaltrials.gov/study/NCT01358877

## Connected records

- pairings: [Early FDG-PET response → chemotherapy omission (HER2+)](https://onco.cc/pairings/pet-adapted-her2-deescalation/)
- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- targets: [HER2](https://onco.cc/targets/her2/), [HER3](https://onco.cc/targets/her3/)
- drugs: [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- trials: [APHINITY](https://onco.cc/trials/aphinity/), [CLEOPATRA](https://onco.cc/trials/cleopatra/), [TRAIN-2](https://onco.cc/trials/train-2/)
- biomarkers: [HER2 IHC 3+ (HER2-positive by immunohistochemistry)](https://onco.cc/biomarkers/her2-ihc-3-plus/)

---
JSON: https://onco.cc/api/v1/entities/dual-her2-blockade.json